DECEMBER 12



8:15am	Welcome word			
8:30-10am	 Pathways leading to atopic diseases and atopic multimorbidity New risk loci associated with atopic multimorbidity Florence DEMENAIS (France) Atopic phenotypes and their implication in the atopic march Adnan CUSTOVIC (UK) Mechanisms underlying allergy and asthma at a molecular level: results from MeDALL studies Erik MELEN (Sweden) 			
10-10:30am	Coffee-Break and poster sessions	s + visit of the exhibition area		
10:30-10:50am	Latest updates on allergy diagnosis Ignacio ANSOTEGUI (Spain)	Food allergy prevention Kirsten BEYER (Germany)	New pathways in environmental allergies Frédéric DE BLAY (France)	Sister Society symposia
10:50-12:00am	OC 1: Molecular allergy to Aspergillus fumigatus in distinguished diagnosis between allergic bronchopulmonary aspergillosis and Aspergillus fumigatus-sensitized asthma in a Southern Chinese Cohort Wenting Luo - The First Affiliated Hospital of Guangzhou Medical University – Guangzhou, China JM OC 2: Novel method for assessing basophil activation by measuring altered expression of membrane-bound and intracellular basogranulin stores Mohammad ALZAHRANI - Al-Baha	OC 6: The impact of cow's milk allergy in infants with failure to thrive: Experience from an Italian Referral Center Lucia Diaferio -Aldo Moro University of Bari - Bari, Italy JM OC 7: Analysis of 10 cases of food protein-induced enterocolitis syndrome due to hen's egg Makoto Nishino - Department of Pediatrics, NHO Sagamihara National Hospital - Sagamihara, Japan JM OC 8: The presence of both hen's egg Ovalbumin allergen and Ovalbumin specific	OC 11: Characterization of the allergenic properties of a pi-class glutathione transferase from Ascaris suum Ana Lozano - Institute for Immunologic al Research, University of Cartagena - Cartagena, Colombia JM OC 12: Identification of a new, no cross-reacting allergen from Ascaris lumbricoides Josefina Zakzuk - University of Cartagena - Colombia JM OC 13: Association of air pollution with severe ocular allergic inflammatory diseases,	



University - Saudi Arabia

OC 3: Protein microarrays: The future of allergy diagnosis? Optimization of coating and printing of allergen arrays used with fluorescent humanised basophil reporter cell line NFAT-DsRed RBL,

<u>Marina KALLI</u> - <u>University of</u> Nottingham, United Kingdom

OC 4: RNA sequencing profiling potential biomarkers for nut allergy,

Khui Hung LEE, Curtin University of Technology, Bentley, Western Australia

OC 5

Immunoglobulin in breastmilk is associated with decreased risk of egg allergy in infants,

<u>V. Verhasselt</u> - University of Western Australia, Australia

OC 9: Toll-like receptor signaling has inverted U-shaped response over time with the Western environment.

<u>J. Guon</u> - Curtin University - Australia <u>OC 10</u> Dai MIYAZAKI, - Tottori University,

Japan

OC 14: Climate change impact on pollen concentrations and air pollution,

<u>Mikhail SOFIEV</u> - _Finnish Meteorological Institute, Finland

OC 15

12:15-1:30pm

Lunch symposia





ASTRAZENECA

1:45-2:30pm

Coffee-Break and poster sessions + visit of the exhibition area

2:30 - 4pm

ILC2 and asthma: what's new?

- ILC2 and severe asthma Anne TSICOPOULOS (France)
- Neuro immune crosstalk in allergic lung inflammation Vijay KUCHROO (USA)
- Negative regulators of ILC2 in asthma Jenny MJÖSBERG (Sweden)

4-4:30pm

Coffee-Break and poster sessions + visit of the exhibition area

WE	4:30-4:50pm
	4:50-6pm

Origins of asthma - genesis Luis CARABALLO (Colombia)	Latest updates on pediatric drug allergy Jean-Christoph CAUBET (Switzerland)	Latest updates on allergen immunotherapy Moises CALDERON (UK)	Sister Society symposia
OC 16: Antibiotic use in the first	OC 21: There are still gaps in the	OC 26: The impact of a Clinical	
year of life as a risk factor for	pre-hospital and hospital	Decision Support System on	
asthma symptoms. What is new	management of anaphylaxis in	allergen immunotherapy	
in the association?	children,	prescription in children and	
<u>Estefanía Vasquez-</u> Echeverri -	<u>G. Pouessel</u> - Pediatric department -	adults with seasonal allergic	
Hospital Infantil de México Federico	France	rhinitis	
Gomez, Mexico City, Mexico JM	OC 22: Mutation of NLRC4 in	<u>Stefania Arasi</u> - Bambino Gesù	
OC 17: Metabolic risk profile and	patients affected by severe FPIES	Children's Hospital, IRCCS - Roma,	
risk of future asthma: a	reactions to multiple foods,	Italy JM	
nationwide cohort study	<u>Valentina PECORA</u> - Children's	OC 27: Basophil activation test is	
<u>Dong Keon Yon-</u> CHA Bundang	Hospital Bambino Gesù - Italy	a useful tool for Hymenoptera	
Medical Center, Seongnam - South	OC 23: Changes of allergic	venom immunotherapy follow-	
Korea JM	disease prevalence at the age of	up,	
OC 18: Gene signatures of	5 years with a 12-year interval,	Pascale NICAISE ROLAND - Bichat	
responders vs. non-responders to	<u>Chizuko SUGIZAKI</u> - Sagamihara	hospital, Immunology - France	
inhaled endotoxin challenge,	National Hospital - Japan	OC 28: Specific IgG4/IgE	
<u>David PEDEN</u> - University of North	OC 24	response after rapid	
Carolina - United States	OC 25	desensitization to low-dose oral	
OC 19: We are what we		immunotherapy with adjunct	
experienced before birth: Lessons		omalizumab in multi-food	
from Epigenetics,		allergic patients,	
Saskia TRUMP, Universitätmedizin		<u>Sayantani SINDHER</u> - Stanford	
Berlin and Berlin Institute of Health -		University - United States	
Germany		OC 29: Pharmacoeconomics of	
OC 20		allergy immunotherapy versus	



		pharmacotherapy, <u>Linda COX</u> - University of Miami - United States <u>OC 30</u>	
6-7:30 pm	WAC OPENING		
7:30-9:30 pm	WELCOME RECEPTION		

DECEMBER 13



8:00-9:00am	Breakfast Symposium: Thermofisher WAO MA Consensus				
9:00-10:30am	Novel therapies in skin allergic diseases • Small molecules in skin allergic diseases Audrey NOSBAUM (France) • Biologicals in chronic spontaneous urticaria Marcus MAURER (Germany) • Biologics in atopic dermatitis Thomas BIEBER (Germany)				
10.30-11:00am	Coffee-Break and poster sessions + visit of the exhibition area				
11:00-11:20am	Latest updates on biomarkers and new therapeutics for severe asthma management Arnaud BOURDIN (France)	New strategies to fight food allergies Alessandro FIOCCHI (Italy)	Latest updates in multiple organ allergy involvement Jocelyne JUST (France)	Sister Society symposia	
11:20-12:30am	OC 31: Clinical-economic impact of mepolizumab in patients with	OC 36: Novel dosing strategy of omalizumab during multi-	OC 41: Differences in allergen- positive reactivity distribution		



severe hypereosinophilic asthma

<u>Diego Bagnasco</u> - University of Genoa

- Genoa, Italy **JM**

OC 32: Astonishing low adherence to inhaled therapy characterizes patients with severe asthma treated with biologics

Marco Caminati - Verona University

Hospital, Verona - Italy JM

OC 33: Efficacy of Mepolizumab in patients with previous Omalizumab treatment failure: real life observation,

G. Passalaqua - University of Genoa - Italy

OC 34 OC 35 allergen oral-immunotherapy
<u>Sayantani B. Sindher</u> - Stanford
University Stanford, CA, - USA **JM**

OC 37: Oral immunotherapy for peanut allergy: a systematic review and meta-analysis

Derek Chu - McMaster University,

OC 38: IgE Immunoapheresis for Treatment of Pediatric Patients with Severe Asthma and Multiple

Hamilton - Canada JM

Food Anaphylaxis: a Pilot Study,

<u>Alessandro Fiocchi</u>, Bambino Gesù

Children's Hospital, Italy

OC 39 OC 40 among adults and children in southern China: an investigation based on real-world medical big data,

<u>Haisheng HU</u> - First Affiliated Hospital of Guangzhou Medical University -China

OC 42: Atopy phenotypes in relation to childhood asthma persistence,

<u>Helena PITE</u> - Allergy Center, CUF Descobertas Hospital, CUF Infante Santo Hospital - Portugal

OC 43: Pollen food associated syndrome: the newly described Gibberellin Regulated Protein family,

<u>Pascal PONCET</u> - Institut Pasteur, France

<u>OC 44</u>

OC 45

019

knowledge!

12.45-2:00pm

Lunch symposia







2:15-3:00pm

Coffee-Break and poster sessions + visit of the exhibition area

3:00 - 4:30pm

Drug hypersensitivity: a need for consensus

- Delayed allergic reactions Annick BARBAUD (France)
- Betalactam antibiotics Maria TORRES (Spain)
- Radio contrast media Mario SANCHEZ BORGES (Venezuela)

World Allergy Forum: Advances and Critical Issues in Asthma

- Mechanisms of allergen-induced asthma Luis CARABALLO (Colombia)
- Overuse of corticosteroids in asthma Giorgio WALTER CANONICA, (Italy)
- Biological treatments in asthma Eugene R. BLEECKER, (USA)

4:30-5:00pm



Coffee-Break and poster sessions + visit of the exhibition area

5:00-5:20pm

5:20-6:30pm

Food allergy diagnosis	and
management	

Motohiro EBISAWA (Japan

OC 46: Anaphylaxis caused by lipid transfer proteins: an emerging and unsettling syndrome Filipe Benito-Garcia - CUF Descobertas Hospital, Lisbon, Portugal JM

OC 47: Randomized controlled trial of oral immunotherapy for children with severe cow's milk allergy: heated milk vs. unheated

Profiling reactions to chemotherapy and biologics

Victoria CARDONA (Spain,

OC 51: Tolerance of Iodixanol, a nonionic, isosmolar contrast agent in case of immediate hypersensitivity reactions to radiocontrast media.

Hélène Mascitti- Allergy Service,
Tenon Hospital, AP-HP, Paris-Sorbonne University, France
OC 52: Immediate hypersensitivity to iodinated

contrast media: interest of

New approaches in anaphylaxis management

Luciana KASE TANNO (France,

OC 56: Anaphylaxis in primary care: Systematic review to support quality of management and optimization of healthcare pathways

Myriam Mamodaly- Montpellier
University Hospital, Montpellier,
France JM

OC 57: An Audit on Schools'

Policy Regarding Emergency

Sister Society symposia





milk

<u>Ken-ichi Nagakura</u> - National Hospital Organization Sagamihara National Hospital, Kanagawa, Japan

JM

OC 48: Ara h 6-specific IgE is a good predictor of peanut allergy in Japanese children,

<u>Sakura Sato</u>- National Hospital Organization Sagamihara National Hospital, Japan

OC 49: highlighting of allergens found in edible crickets (ornithachris turbida cavroisi) from Niger using 2D western blot,

<u>Tahirou Hamidou</u>- Lamordé hospital of Niamey, Niger

OC 50: Advances in alpha gal allergy.

<u>Michael Levin</u>- University of Cape Town, South Africa intravenous challenge test with low dose in addition of skintesting.

<u>Sébastien Lefevre</u>- Metz Regional Hospital, France

OC 53:

OC 54:

OC 55:

Adrenaline Auto-Injector Use and Provision of Spare Pens in the East and North Hertfordshire Region of the UK <u>Michael Ha- Lister Hospital</u>,

<u>міспаеі на</u>- Lister но*s*ріtc

Stevenage, UK **JM**

OC 58: The distribution of diagnoses of anaphylactic syndromes in the search for idiopathic anaphylaxis over a 15 years period at an academic medical center,

<u>P. Greenberger</u>- Northwestern University Feinberg School of Medicine, United States

OC 59: Food-induced anaphylaxis phenotype in infancy:

a retrospective analysis,
<u>G. Pouessel</u>- Department of

pediatrics, France

OC 60



DECEMBER 14




				Update you
8:00-9:00am	Breakfast symposium			
9:00-10:30am	Climate change, air pollution and health impact of airborne biological particles			
	Climate change: consequences	and indirect effects on the allergy s on pollination and sporilation Jo ly pollens but also mold Gennaro		ANO (France)
10.30-11:00am	Coffee-Break and poster sessions	s + visit of the exhibition area		
11:00-11:20am	Latest updates in Drug Allergy Didier EBO (Belgium)	Latest updates on upper respiratory tract allergies Philippe GEVAERT (Belgium)	Understanding the pathophysiology of asthma Hamida HAMMAD (Belgium)	Sister Society symposia
11:20-12:30am	OC 61: Incidence of and risk factors for perioperative and periprocedural anaphylaxis in the United States Alexei Gonzalez-Estrada - Mayo Clinic, Jacksonville, FL, USA JM OC 62: Drug allergy in primary care: systematic review to support quality of management and optimization of healthcare pathways Clara Gaudin - Montpellier, University Hospital, Montpellier, France JM OC 63: Desensitization to penicillin is safe and effective in	OC 66: Phenotypes of allergic rhinitis: the application of stratified and personalized medicine in the rhinitis field Irina Shchurok - Novicau, Vitebsk, Belarus JM OC 67: What did the doctor say? Patients' comprehension of allergy consultations in a French university hospital Marcin Trzmielewski - Montpellier University Hospital, Montpellier, France JM OC 68: Dupilumab Improves Upper and Lower Airway	OC 71: The role of polyprenol in overcoming steroid insensitivity in asthma Ivans Sergejs_Kuznecovs - Public Health Research Laboratory, Riga, Latvia JM OC 72: To study the role of T regulatory cells in developing asthma in a birth cohort of babies with family history of allergies Amit Agarwal - Postgraduate Institute of Medical education and Research, Chandigarh, India JM OC 73: ADAM33 in Bulgarian	
Mus	allergic pregnant women with	Outcome Measures in Patients	children with severe asthma	



syphilis,

With CRSwNP With NSAID-ERD:

<u>Polina Shahid</u> - Medical University,





(Austria)	Harald RENZ (Germany)	dermatitis
		Angèle SORIA (France)
OC 76: A novel mechanism of	OC 81: The early life trajectory of	OC 86: Supporting the
IgE regulation by IgE-allergen	infant gut microbiota and atopic	optimization of health-care
complexes via CD23,	asthma at 10 years-of-age in a	pathways of and reduction of the
Monique Vogel- University of Bern,	US birth cohort <u>,</u>	burden of urticaria to patients
Switzerland	<u>Christine Johnson</u> - Henry Ford Health	and society: a systematic review
OC 77: Optimal TH2A effector	System, USA	Evangéline Clark- Montpellier
function requires local epithelial	OC 82: Circulating neutrophil and	University Hospital, Montpellier,
cytokine signaling,	eosinophil extracellular traps are	France JM
<u>Erik Wambre</u> - Benaroya Research	markers of severe asthma <u>.</u>	OC 87: Dolichyl phosphate
Institute, United States	<u>Luc de Chaisemartin,</u> APHP- Bichat	deficiency and polyprenol
OC 78: TGM2+ IFN-gamma	Hospital, Immunology, France	supplementation in the
secreting circulating innate	OC 83: Circulating B cells	treatment of atopic dermatitis
lymphoid cell precursors (ILCPs)	upregulate antiviral response and	<u>Galina Kuznecova</u> - Public Health
are enhanced in children with	carry viral particles after	Research Laboratory, Riga, Latvia JM
celiac disease.	experimental rhinovirus infection	OC 88: Economic burden of
<u>Sara Trabanelli</u> - Department of	of healthy and asthmatic	chronic urticaria in Brazil: a one-
Oncology UNIL CHUV and Ludwig	subjects <u>, Mübeccel Akdis</u> - Swiss	year real life study <u>.</u>
Institute for Cancer Research,	Institute of Allergy and Asthma	<u>Priscilla Santos</u> - Hospital
University of Lausanne, Switzerland	Research (SIAF), Suisse	Universitário Pedro
OC 79: miR103a-3p in exosomes	OC 84: Modern urbanization has	Ernesto/Universidade do Estado do
derived from human mast cells	re-shaped the bacterial	Rio de Janeiro, Brazil
(MCs) following aggregation of	microbiome profiles of house	OC 89: Staphylococcus dysbiosis
FceRI enhances IL-5 production	dust in domestic environments,	correlates of success of treatment
from IL-33-stimulated type2	<u>Yifan Shan</u> - School of Public Health,	of atopic dermatitis with the
innate lymphoid cells (ILC2) via	Xinxiang Medical University. China,	JAK/SYK inhibitor ASN002,
silencing protein arginine	OC 85: Gut microbiota profile in	<u>Avidan Neumann</u> - Institute
methyltransferase (PRMT),	infants with milk and/or egg	Environmental Medicine (IEM),
		Helmholtz Center Muich, Germany

3:20-4:30pm



Yoshimichi Okayama- Nihon University School of Medicine, Japan OC 80:	allergy and evaluation of intestinal colonization and persistence of a probiotic mixture, <u>Maurizio Mennini</u> - Division of Allergy, <u>Bambino Gesù Children's Hospital</u> <u>IRCCS</u> , Italy	OC 90	
END OF THE CONFERENCE			



4:30pm

